The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.
Data last updated: Oct 16, 2026
Snapshot (as of Oct 16, 2026): Gilead Sciences, Inc. (GILD) pays a $3.22 annual dividend ($0.82 quarterly), yielding 2.22% at $157.37/share. Next ex-dividend date 2026-09-15. 9+ consecutive years of dividend growth. Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 2.22%
Annual Dividend: $3.22 per share
Payout Ratio: 43.5%
Ex-Dividend Date: 2026-09-15
Dividend Frequency: quarterly
Sector: Healthcare
Years of Dividend History: 12
Gilead Sciences, Inc. dividend comes from a biopharmaceutical company best known for HIV treatments like Biktarvy and Descovy, along with oncology therapies such as Yescarta and Trodelvy. GILD currently yields 2.17%, with trailing twelve-month payments of $3.22 per share. The company pays quarterly, with the next ex-dividend date set for September 15, 2026. A beta of 0.332 points to low price volatility, which suits income investors who prioritize a steady payout over share price swings.
Gilead Sciences, Inc. pays out 43.5% of earnings as dividends, a payout ratio classified as moderate (40–60%). That level leaves meaningful room to sustain payments, supported by a portfolio of treatments addressing chronic conditions like HIV-1 infection, where demand is ongoing rather than episodic. Gilead Sciences, Inc. dividend safety faces its most visible pressure from pipeline risk: the company operates in drug development, where patent expirations and clinical setbacks can shift earnings materially. Nothing in the current payout ratio signals immediate stress, but the business is not immune to revenue disruption.
Gilead Sciences, Inc. dividend history shows a CAGR of 6.2% per year from 2016 to 2025. Per-share payments grew from $1.84 to $3.16 over that window (2026 is a partial year and excluded from the CAGR calculation). The smallest annual increase in the window was 2.6% in 2025, which is a meaningful step down from the 13.0% increase posted in 2017. Growth is real, but the pace has clearly slowed in recent years.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | +2.7% | $2.92 (2022) | $3.16 (2025) |
| 5-Year | +3.0% | $2.72 (2020) | $3.16 (2025) |
| 10-Year | +9.4% | $1.29 (2015) | $3.16 (2025) |
GILD stock fits dividend investors who want a moderate, recurring income stream from a company with a durable product base in HIV and oncology. The current yield of 2.17% sits in the moderate (2–4%) range, and it runs below the 5-year average yield of 3.33%, meaning buyers today are paying up relative to historical norms. Nine consecutive years of increases and a 43.5% payout ratio give the dividend a credible foundation. The trade-off is straightforward: growth has slowed to low single digits, and the yield is not high enough to compensate if price appreciation stalls. Income without excitement, but without obvious cracks either.
| Payment Date | Amount per Share |
|---|---|
| 2026-09-15 | $0.8200 |
| 2026-06-15 | $0.8200 |
| 2026-03-13 | $0.8200 |
| 2025-12-15 | $0.7900 |
| 2025-09-15 | $0.7900 |
| 2025-06-13 | $0.7900 |
| 2025-03-14 | $0.7900 |
| 2024-12-13 | $0.7700 |
| 2024-09-13 | $0.7700 |
| 2024-06-14 | $0.7700 |
| Year | Total Dividends |
|---|---|
| 2026 | $2.4600 |
| 2025 | $3.1600 |
| 2024 | $3.0800 |
| 2023 | $3.0000 |
| 2022 | $2.9200 |
Project income from GILD with the GILD dividend calculator or track your full portfolio with the dividend tracker.